Glycomics/Glycobiology Market Size, Share, By Product Type (Enzymes, Instruments, Kits & Reagents, and Others), Application (Drug Discovery and Development, Diagnostics, and Others), End-User (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, CROs, and Others), and Region - Trends, Analysis, and Forecast till 2035

• By 2035, the market is expected to enlarge at USD 10.1 Billion.
• Glycomics/glycobiology market size was valued at USD 2.4 Billion in 2024.
• Target market is developing at a CAGR of 15.6%.

Glycomics is the study of the structure and function of glycans in cells and organisms. Additionally, it is a high-throughput field that analyzes the structure of glycans in an organism. Glycobiology is the study of the structure, biosynthesis, biology, and evolution of glycans. It also studies the proteins that recognize glycans. Therefore, glycomics and glycobiology are fields of study that focus on the structure and function of carbohydrates, also known as glycans, in organisms. There are various positive impacts of glycomics and glycobiology. In addition to this, increased government investment, more research and development projects, and technological advancements are further contributing to the glycomics/glycobiology market growth.

Impact of AI on the Glycomics/Glycobiology Market:

Artificial Intelligence (AI), when integrated with glycomics/glycobiology, unlock various applications. This includes, to understand glycosylation phenotypes, to understand glycan-linked disease pathogenesis, to decipher complex glycosylation machinery, to develop therapies to offset effects of aberrant glycosylation, and to enhance current glycomics tools.

Key Drivers of Target Market:

Disease Identification Property of Glycomics and Glycobiology is Fostering the Market Growth

Glycomics and glycobiology are fields of study that can help identify disease-specific glycan patterns and develop new drugs. Glycomics can help in identifying disease-specific patterns of glycans and develop drugs that target glycan-related pathways. Glycomics and glycobiology together can help identify potential therapeutic targets and develop drugs that target glycan-related pathways.

• For instance, in September 2024, CD BioGlyco, a leading provider of glycobiology research services, announced the launch of its glycobiology disease model development service. This service leverages advanced glycobiology technologies and methods to construct and validate high-quality disease models that simulate the role of abnormal glycosylation in various diseases. This model helped in identifying diseases, such as cancer, infectious diseases, and influenza.

Restraints:

Molecular Complexity of Glycomics and Glycobiology is Limiting the Market Expansion

The immense variety and intricate structures of glycans, which can be attached to proteins and lipids, creating a vast array of possible combinations are far more diverse than the simpler linear structures of DNA or proteins. This makes glycomics and glycobiology extremely challenging to comprehensively study and analyze the glycome (the complete set of glycans in an organism) due to its high degree of structural diversity.

• Counterbalance Statements: The molecular complexity in glycomics and glycobiology may be addressed by sophisticated analytical methods, computational instruments, and systems biology approaches, allowing for an effective comprehension of glycan structures and its functions.

Opportunities:

Glycomics and Glycobiology Integrated with Advanced Technologies Opens Up Opportunities in the Upcoming Years

The study of carbohydrates and its biological function is known as glycobiology and glycomics. Glycans and glycoproteins can be studied using advanced technologies, such as mass spectrometry, high-performance liquid chromatography (HPLC), and lectin and antibody microarrays.

• For instance, in July 2024, according to the article published by Springer Nature Limited, CandyCrunch, a deep learning-based tool that predicted glycan structures from tandem mass spectrometry (MS/MS) data with high accuracy, aiming to homogenize structural glycomics by enabling high-throughput analysis and reducing reliance on expert annotation.

Product type, application, end-user, and region are the segmentations of this market. 

Product Type

On the foundation of product type, the market is classified into enzymes, instruments, kits, reagents, and others. The enzymes segment is growing with the highest CAGR as it is selective, consistent, and efficient. It is widely used in research and development, such as glycan analysis, diagnostics, and drug discovery.

• For instance, in January 2024, Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions and Navinci Diagnostics, leader of innovative in situ proximity ligation assay-based solutions, announced that it had signed an agreement to develop cutting-edge biomarker discovery tools, allowing detection of specific protein glycosylation in tissue samples for the first time.

Application

On the basis of application, the market is grouped into drug discovery and development, diagnostic, and others. The drug discovery and development segment holds the biggest market share as glycomics and glycobiology provide insights into disease mechanisms, which can further help in the development of new drugs and diagnostic tools.

• For instance, in July 2023, Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, announced the acquisition of Quanta BioDesign, the inventor of discrete polyethylene glycol (dPEG) technology for advanced bioconjugate and payload delivery design for life science and biopharma applications. The aim of this acquisition was to continue the work on monodispersed dPEG reagents for further drug discovery and diagnostic development.

End-User

Based on end-user, the market is divided into academics and research institutes, pharmaceutical and biotechnology companies, CROs, and others. The academic and research institutes segment is dominating the market due to increase in research funding and activity in drug discovery. Additionally, it is extensively used for data analysis of glycan structure.

• For instance, in March 2022, Massachusetts Life Sciences Center awarded HMS Center for Glycoscience, the NCFG and the Glycomics Core at for the project titled "Innovative Glycoscience for Diagnostic and Therapeutic Advances".  This was vital for the development of glycosciences such as glycomics, glycobiology and other glycosciences, and other medical advancements in this area.

Region

By region, the market is bifurcated into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America: North America holds the biggest glycomics/glycobiology market share due to the region’s strong research infrastructure, government funding, prominent market players, investment in research and development by public and private entities, and investments in biotechnology.

• For instance, in December 2023, GlycoMimetics, Inc., a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, announced the 65th American Society of Hematology (ASH) Annual Meeting and would feature two presentations on uproleselan, including an investigator-initiated trial (IIT) which studied the first-in-class E-selectin antagonist in patients with treated secondary Acute Myeloid Leukemia (ts-AML). Both the presentations were on glycobiology-based therapies.

Asia Pacific: This region has the fastest growing market during the forecast period. This is due to the region’s rapid economic growth, substantial investments in healthcare research, supportive government policies, and a rising number of research institutes.

Glycomics/Glycobiology Market Report Scope:

Segmentation:

By Product Type:

• Enzymes
  • Glycosidases
  • Transferases
• Instruments
  • Mass Spectrometry
  • Chromatography
  • Arrays
• Kits
• Reagents
• Others

By Application:

• Drug Discovery and Development
• Diagnostics
• Others

By End User:

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• CROs
• Others

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Russia
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • Indonesia
  • Malaysia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating in the market are Thermo Fisher Scientific Inc., New England Biolabs, Promega Corporation, Merck KGaA, Waters Corporation, and others. These companies adopt strategies, such as product development, market penetration, and strategic partnerships to maintain their dominance in the market.

List of Key Players in the Market:

• Thermo Fisher Scientific Inc.
• New England Biolabs
• Promega Corporation
• Merck KGaA
• Waters Corporation
• Takara Bio Inc.
• Bio-Techne
• Agilent Technologies, Inc.
• Sumitomo Bakelite Co., Ltd.
• Bruker
• Pegasus Laboratories, Inc.
• Shimadzu Corporation
• Danaher
• RayBiotech, Inc.

• In January 2025, BioGlyco, a leading provider of services and products in the field of glycobiology, announced the launch of its new sub-brand, Marine Glycobiology, which offer a wide range of services and products tailored to meet the diverse needs of researchers and industries worldwide. Glycans originating from marine sources are different from terrestrial sources, thereby is an important resource for discovering new biomolecules for research and development.
• In August 2022, Griffith University’s Institute for Glycomics was supposed to launch an Australian-first center dedicated to deciphering the cancer glycol-code, which was funded by Australian Cancer Research Foundation (ACRF). The ACRF International Centre for Cancer Glycomics would enable the Institute’s researchers to determine changes to the glycomics and its interactions with proteins and lipids in a number of cancers.

Analyst View:

The benefits of glycobiology and glycomics are numerous. Disease detection, drug effectiveness tracking, treatment development, understanding disease mechanisms, tissue structure preservation, cell signaling, and immunological response are all included in this. These elements support the growth of the glycomics and glycobiology market.

More Related Reports

Enzymes Market
Molecular Biology Enzymes Kits & Reagents Market
Specialty Enzymes Market
Sepsis Diagnostics Market
Food Diagnostics System Market